TMJ 'dysfunction' - Health implications

ECTRIMS Highlights 2012
Posted: 15 Oct 2012 06:40 AM PDT

In response to a request by one of the readers, the following is a list of my ECTRIMS highlights or insights for 2012:

1. Simvastatin 80mg per day reduced brain atrophy and delayed disease progression in MSers with SPMS.
Where to from here?
Dr Chataway will have to find a way of getting funding to do two large phase 3 clinical trials to get the drug licensed for progressive MS.

As Simvastatin is off-patent, this will be almost impossible. The trials required will cost upward of $100M (one commentator said to me close to $500M).
This is why we need drugs that have a suitably long patent life so that industry can get involved. For those of you attacking Pharma please remember that at the present time, they are the only ones with deep enough pockets and the willingness to take the risks of failing.

Big Pharma is simply the only show in town. When it comes to taking innovations from the bench to the bedside. If you disagree, please let me know how; we have a list of at least 10 ideas that need translating.

Chataway, et al. The MS-STAT trial: high dose simvastatin demonstrates neuroprotection without immune-modulation in secondary progressive multiple sclerosis (SPMS) – a phase II trial.

Comment: I hope this is some kind of joke!
The bluff and intrigue is incredible.
Challenging the existing standards in dental and medical care comes with significant costs. Through my website and this forum, I have highlighted practices that, whether intentionally or unintentionally, contribute to ongoing illness. This disruption is not welcomed by the authorities overseeing our healthcare system. To continue publishing evidence-based articles, sharing discoveries from my own patients' experiences that have led to their recoveries through a unique approach, and educating thousands of health professionals and patients globally, we require some support. If this article has substantially enhanced your understanding, please consider making a donation through this link: PLEASE CLICK TO DONATE

Thank you! A heartfelt thank you to everyone who has generously contributed. Your support is deeply valued and enables Dr. Amir to persist in his mission of fostering improved dental and medical practices globally.

------------------------------------------------------------------------------------------NOTICE-----------------------------------------------------------------------------------------------
This article is written in accordance with the Human Rights Act 1998: UK Public General Acts 1998 c. 42 SCHEDULE 1 PART I Article 10, with the intent of serving the resilient British public. This legislation clearly states, Everyone has the right to freedom of expression. This right shall include freedom to hold opinions and to receive and impart information and ideas without interference by public authority. We are committed to addressing any form of harassment, whether direct or indirect, by government bodies or their affiliates, in line with this act and the principles that protect freedom of expression. Additionally, any breaches of the Data Protection Act will be promptly reported to the Information Commissioner's Office and The Law Society ..................................................................................................................................................................................................................................
Disclaimer: This educational article focuses on health benefits from individual perspectives and doesn't imply widespread results. Important to seek a doctor's advice before taking action. It's meant to enhance, not substitute for, medical advice and doesn't detail all possible uses or risks. Always prioritize professional medical advice over information read here.

FDA warning on Statins (obviously omitted by the media)

Lipitor:What is the best-selling drug in the history of pharmaceuticals? What made $125 billion in 14 and a half years and as much as $11 billion in a single year? Lipitor, Pfizer's blockbuster statin drug, owed its success to two factors. It was launched in 1997 when direct-to-consumer drug advertising was just beginning and it harnessed the growing national fear of cholesterol-linked heart attacks.

Thanks to Lipitor's "Know Your Numbers" TV ads and Pfizer reps who saturated medical offices with free samples of the white pills and sometimes lunch, more than 29 million people were prescribed Lipitor.

But in 2012—the same year Lipitor's patent expired—those 29 million people (and millions taking other statins) got a surprise from the FDA. The agency made a label change warning that Lipitor and other statins could cause diabetes, liver injury, muscle damage and memory impairment. Who knew? The quartet of concerns "should not scare people off statins," said Amy G. Egan, deputy director for safety in the FDA’s Division of Metabolism and Endocrinology Products. Right.

http://www.alternet.org/personal-health ... 1#bookmark
By Martha Rosenberg